CORCEPT THERAPEUTICS INC - Form 4 Filing

William Guyer, Chief Development Officer of CORCEPT THERAPEUTICS INC, reported a series of transactions on July 7, 2026. Guyer acquired 20,000 shares of Common Stock through the exercise of a stock option at a price of $0.00 per share. Concurrently, he disposed of 19,048 shares of Common Stock at a weighted average price of $93.11 and 19,048 shares at a weighted average price of $93.54. These disposals were made pursuant to a 10b5-1 plan. The filing also notes that 224 shares underlying unvested restricted stock awards granted on December 1, 2025, 498 shares granted on March 2, 2026, and 877 shares granted on June 1, 2026, are included in the post-transaction share count, with full vesting on the one-year anniversary of the grant date. The option exercised is for 20,000 shares of Common Stock with an exercise price of $21.65 and an expiration date of September 1, 2031.